DOC1021 Cell-based Immunotherapy in Combination With Standard Chemoradiation for Adjuvant Therapy of Glioblastoma: Early Results From an Expanded Access Protocol of a Phase I Trial (P11-6.010)

Key Points

• The study aims to report the results of an expanded access protocol for DOC1021 in glioblastoma patients.
• Expanded access protocol evaluating DOC1021.
• Included adult patients with new or recurrent glioblastoma.
• Observational components of a phase I trial.
• Initial results indicate promising responses in some patients receiving DOC1021.
• Early data suggest potential safety and efficacy when combined with standard chemoradiation.